215 related articles for article (PubMed ID: 16879756)
41. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.
Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Picchio G; Sarrazin C
Antivir Ther; 2014; 19(6):559-67. PubMed ID: 24584086
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.
Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; McGovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M;
J Infect Dis; 2015 Nov; 212(9):1407-19. PubMed ID: 25883387
[TBL] [Abstract][Full Text] [Related]
44. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
45. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM.
Lambers FA; Prins M; Thomas X; Molenkamp R; Kwa D; Brinkman K; van der Meer JT; Schinkel J;
AIDS; 2011 Nov; 25(17):F21-7. PubMed ID: 21857492
[TBL] [Abstract][Full Text] [Related]
46. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
[No Abstract] [Full Text] [Related]
47. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
48. New kinetic models for the hepatitis C virus.
Perelson AS; Herrmann E; Micol F; Zeuzem S
Hepatology; 2005 Oct; 42(4):749-54. PubMed ID: 16175615
[TBL] [Abstract][Full Text] [Related]
49. Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials.
Sypsa V; Hatzakis A
Stat Med; 2008 Dec; 27(30):6505-21. PubMed ID: 18951370
[TBL] [Abstract][Full Text] [Related]
50. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
Guedj J; Yu J; Levi M; Li B; Kern S; Naoumov NV; Perelson AS
Hepatology; 2014 May; 59(5):1706-14. PubMed ID: 24375768
[TBL] [Abstract][Full Text] [Related]
51. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.
Neumann AU; Lam NP; Dahari H; Davidian M; Wiley TE; Mika BP; Perelson AS; Layden TJ
J Infect Dis; 2000 Jul; 182(1):28-35. PubMed ID: 10882578
[TBL] [Abstract][Full Text] [Related]
52. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
[TBL] [Abstract][Full Text] [Related]
53. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
[TBL] [Abstract][Full Text] [Related]
54. Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.
Salamov G; Holms R; Bessler WG; Ataullakhanov R
Arzneimittelforschung; 2007; 57(7):497-504. PubMed ID: 17803064
[TBL] [Abstract][Full Text] [Related]
55. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients.
Shaker O; Ahmed A; Doss W; Abdel-Hamid M
J Viral Hepat; 2010 Nov; 17(11):794-9. PubMed ID: 20002306
[TBL] [Abstract][Full Text] [Related]
56. Estimation and inference on correlations between biomarkers with repeated measures and left-censoring due to minimum detection levels.
Xie X; Xue X; Gange SJ; Strickler HD; Kim MY;
Stat Med; 2012 Sep; 31(21):2275-89. PubMed ID: 22714546
[TBL] [Abstract][Full Text] [Related]
57. Linear and nonlinear mixed-effects models for censored HIV viral loads using normal/independent distributions.
Lachos VH; Bandyopadhyay D; Dey DK
Biometrics; 2011 Dec; 67(4):1594-604. PubMed ID: 21504417
[TBL] [Abstract][Full Text] [Related]
58. A mechanistic nonlinear model for censored and mismeasured covariates in longitudinal models, with application in AIDS studies.
Zhang H; Wong H; Wu L
Stat Med; 2018 Jan; 37(1):167-178. PubMed ID: 29034494
[TBL] [Abstract][Full Text] [Related]
59. Regression analysis of case K interval-censored failure time data in the presence of informative censoring.
Wang P; Zhao H; Sun J
Biometrics; 2016 Dec; 72(4):1103-1112. PubMed ID: 27123560
[TBL] [Abstract][Full Text] [Related]
60. Estimating the odds ratio when exposure has a limit of detection.
Cole SR; Chu H; Nie L; Schisterman EF
Int J Epidemiol; 2009 Dec; 38(6):1674-80. PubMed ID: 19667054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
